BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12086885)

  • 1. Perspectives on the development of a molecularly targeted agent.
    Druker BJ
    Cancer Cell; 2002 Feb; 1(1):31-6. PubMed ID: 12086885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STI571 (Gleevec) as a paradigm for cancer therapy.
    Druker BJ
    Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STI571: a paradigm of new agents for cancer therapeutics.
    Mauro MJ; O'Dwyer M; Heinrich MC; Druker BJ
    J Clin Oncol; 2002 Jan; 20(1):325-34. PubMed ID: 11773186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
    O'Dwyer ME; Druker BJ
    Curr Cancer Drug Targets; 2001 May; 1(1):49-57. PubMed ID: 12188891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
    Sawyers CL
    Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STI571 (imatinib mesylate): the tale of a targeted therapy.
    Thambi P; Sausville EA
    Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
    Cowan-Jacob SW; Guez V; Fendrich G; Griffin JD; Fabbro D; Furet P; Liebetanz J; Mestan J; Manley PW
    Mini Rev Med Chem; 2004 Mar; 4(3):285-99. PubMed ID: 15032675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
    Deininger MW
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
    Gambacorti C
    Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [STI571: a summary of targeted therapy].
    Czyz M; Jakubowska J
    Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 16. STI571: a magic bullet?
    Verweij J; Judson I; van Oosterom A
    Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STI571: a gene product-targeted therapy for leukemia.
    Mauro MJ; Druker BJ
    Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
    Mauro MJ; O'Dwyer ME; Druker BJ
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S77-8. PubMed ID: 11587372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.